BioSpace News Archive

Policy

60 Degrees Pharmaceuticals Receives FDA Comments on Tafenoquine-Babesiosis Clinical Trial Protocol; No Material Changes Required

60 Degrees Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has provided comments on the protocol of a planned clinical trial that will study the use of tafenoquine in treating babesiosis.

May 2, 2024
·
9 min read
Business

Mineralys Therapeutics to Announce First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 9, 2024

Mineralys Therapeutics, Inc. today announced it will report its financial results from the first quarter ended March 31, 2024, before the financial markets open on Thursday, May 9, 2024.

May 2, 2024
·
1 min read
Business

Vicinitas Therapeutics Appoints Adam Hughes as Chief Scientific Officer

Vicinitas Therapeutics today announced the appointment of Adam Hughes, Ph.D., as Chief Scientific Officer.

May 2, 2024
·
3 min read
Business

MindMed to Host Conference Call and Webcast to Discuss First Quarter 2024 Financial Results and Provide Business Update

Mind Medicine announced today that it plans to host a conference call on Wednesday, May 8, 2024, at 4:30 p.m. ET to provide a corporate update and review the Company’s results for the first quarter ended March 31, 2024.

May 2, 2024
·
1 min read
Business

Altimmune to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024

Altimmune, Inc., a clinical-stage biopharmaceutical company, announced that it will report its first quarter 2024 financial results on Thursday, May 9, 2024 and will provide a business update.

May 2, 2024
·
1 min read
Business

Arbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024

Arbutus Biopharma Corporation today announced that after a distinguished 38-year career, the Company’s co-founder and Chief Scientific Officer, Dr. Michael Sofia, will retire effective December 31, 2024.

May 2, 2024
·
5 min read
Business

Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2024 Earnings and Company Updates

Intellia Therapeutics, Inc., a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, will present its first quarter 2024 financial results and operational highlights in a conference call on May 9, 2024, at 8 a.m. ET.

May 2, 2024
·
1 min read
Business

Anavex Life Sciences to Announce Fiscal 2024 Second Quarter Financial Results on Thursday, May 9th, 2024

Anavex Life Sciences Corp. announced that it will issue financial results for its fiscal quarter ended March 31, 2024, on Thursday, May 9, 2024.

May 2, 2024
·
3 min read
Genetown

Biogen Reports Progress on Corporate Responsibility Priorities

Biogen Inc. announced publication of its 2023 Corporate Responsibility Report detailing progress on the company’s commitment to making responsible business decisions in the best interests of all its stakeholders.

May 2, 2024
·
7 min read
Business

Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update

Arbutus Biopharma Corporation today reports first quarter 2024 financial results and provides a corporate update.

May 2, 2024
·
17 min read